TABLE 6.

Pharmacological treatments reversing the sexual inhibition of sexually satiated male rats.

Neurotransmitter system	Drug (doses) and administration route	Mechanism of action	References
GABAergic system	Bicuculline (0.01−0.3 mg/kg), i.p. Bicuculline (50 ng/rat), intra-VTA	GABA-A receptor antagonist	Rodríguez-Manzo and Canseco-Alba, 2017
Glutamatergic system	Ketamine (0.01−0.3 mg/kg), i.p.	Non-competitive NMDA receptor antagonist	Rodríguez-Manzo, 2015
	CNQX (0.001−0.003 mg/kg), i.p.	AMPA receptor antagonist
	MPEP (0.03 mg/kg), i.p.	mGluR5 receptor antagonist
Noradrenergic system	Yohimbine (2.0−4.0 mg/kg), i.p.	α2-adrenoceptor antagonist	Rodríguez-Manzo and Fernández-Guasti, 1994
Serotonergic system	8-OH-DPAT (0.25−0.5 mg/kg) i.p.	5-HT1A receptor agonist	Rodríguez-Manzo and Fernández-Guasti, 1994
Dopaminergic system	Apomorphine (25−100 μg/kg), i.p.	Non-selective DA receptor agonist	Guadarrama-Bazante et al., 2014
	SKF38393 (3.0 mg/kg), i.p.	D1-like DA receptor agonist
	Apomorphine (0.6−6.0 μg/rat), intra-NAcc	Non-selective DA receptor agonist	Guadarrama-Bazante and Rodríguez-Manzo, 2019
	Quinpirole (0.3−1.0 μg/rat), intra-NAcc Quinpirole (0.3 μg/rat), intra-mPOA	D2-like DA receptor agonist
Opioidergic system	Naloxone (3.0 mg/kg), i.p. Naltrexone (0.2 mg/kg), i.p.	μ and δ opioid receptor antagonists	Rodríguez-Manzo and Fernández-Guasti, 1995a
	Naltrexone (0.3 μg/rat), intra-VTA	μ and δ opioid receptor antagonist	Garduño-Gutiérrez et al., 2013
Endocannabinoid system	AEA (0.1−0.3 mg/kg), i.p.	CBR agonist	Canseco-Alba and Rodríguez-Manzo, 2014
	AEA (0.01−0.03 μg/rat), intra-VTA	CBR agonist	Canseco-Alba and Rodríguez-Manzo, 2016
	2-AG (0.1−3.0 mg/kg), i.p.	CBR agonist	Canseco-Alba and Rodríguez-Manzo, 2019a

i.p., intraperitoneal; intra-VTA, infused into the ventral tegmental area; intra-NAcc, infused into the nucleus accumbens; intra-mPOA, infused into the hypothalamic medial preoptic area.